What are the first line treatment options in HCC patients with significant baseline proteinuria?
Would you consider single agent IO such as Nivolumab, given data are not strong (Checkmate 459)?
Answer from: Medical Oncologist at Academic Institution
Tough problem! Treatment of advanced HCC is quite challenging since medical oncologists have to account for the compromised liver function (due to the underlying liver disease) over and beyond the disease burden, when making treatment decisions. Therefore, treatment decisions are often made after we...